A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

NCT04203719 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Head, Neck and Chest Cancer

Interventions

DRUG: AK105
DRUG: Anlotinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.